10-Q: Tandem Diabetes Reports Mixed Q3, YTD Losses Mount

Tandem Diabetes Care reports increased sales and improved gross margins for Q3 and YTD 2025, but a significant rise in year-to-date net loss driven by one-time expenses.

Summary

• Total sales for the three months ended September 30, 2025, increased to $249.3 million, up from $244.0 million in the prior year, a 2.2% increase.
• Total sales for the nine months ended September 30, 2025, rose to $724.4 million, compared to $657.6 million for the same period in 2024, a 10.2% increase.
• Gross profit for the three months ended September 30, 2025, was $134.3 million, with a gross margin of 54%, up from 51% in Q3 2024.
• Gross profit for the nine months ended September 30, 2025, was $378.6 million, with a gross margin of 52%, up from 51% in YTD 2024.
• Net loss for the three months ended September 30, 2025, improved to $(21.2) million, compared to $(23.3) million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, significantly worsened to $(204.1) million, compared to $(96.8) million in YTD 2024.
• Operating expenses for the nine months ended September 30, 2025, increased by $143.4 million, primarily due to a $75.2 million charge for acquired in-process research and development (IPR&D) and $20.0 million in litigation and settlement expense.
• Cash and cash equivalents increased to $91.9 million at September 30, 2025, from $69.2 million at December 31, 2024.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $(19.5) million, a decrease from $13.5 million provided in the same period of 2024.
• The company received CE Mark approval for the Tandem Mobi insulin delivery system with Control-IQ+ technology in May 2025.

Sentiment

Score: 3

Explanation: While the company achieved revenue growth and improved gross margins, particularly in the third quarter, the significant increase in year-to-date net loss and operating loss, driven by substantial one-time expenses (IPR&D and litigation), indicates considerable financial headwinds. The negative operating cash flow and reduction in stockholders' equity further contribute to a cautious outlook, despite promising strategic product developments and market expansion efforts.

Positives

• Sales increased by 2.2% for the three months and 10.2% for the nine months ended September 30, 2025, demonstrating continued revenue growth.
• Gross margin improved to 54% for the three months and 52% for the nine months ended September 30, 2025, indicating better cost management or pricing.
• Net loss for the three months ended September 30, 2025, improved to $(21.2) million from $(23.3) million in the prior year quarter.
• Operating loss for the three months ended September 30, 2025, improved to $(22.9) million from $(26.1) million in the prior year quarter.
• The Tandem Mobi insulin delivery system with Control-IQ+ technology received CE Mark approval in May 2025, enabling international expansion.
• The passage of the One Big Beautiful Bill Act (OBBBA) in July 2025 led to a reduction in domestic cash tax expense due to immediate expensing of domestic research and development expenditures.
• Cash and cash equivalents increased to $91.9 million at September 30, 2025, from $69.2 million at December 31, 2024, improving liquidity.
• Net cash provided by investing activities significantly improved to $87.9 million for the nine months ended September 30, 2025, compared to $(28.5) million used in the prior year period.

Negatives

• Net loss for the nine months ended September 30, 2025, significantly worsened to $(204.1) million, compared to $(96.8) million in the prior year period.
• Operating loss for the nine months ended September 30, 2025, significantly worsened to $(195.6) million, compared to $(98.5) million in the prior year period.
• Operating expenses for the nine months ended September 30, 2025, increased substantially by $143.4 million, driven by a $75.2 million charge for acquired in-process research and development (IPR&D) and $20.0 million in litigation and settlement expense.
• Pump shipments decreased in both the United States (from nearly 21,000 to more than 20,000) and outside the United States (from nearly 11,000 to more than 9,000) for the three months ended September 30, 2025.
• Outside the United States pump shipments decreased due to distributor destocking in anticipation of the initiation of direct sales activities in select countries.
• The company recognized a $2.7 million loss from equity method investments for the three months and $9.6 million for the nine months ended September 30, 2025.
• Total stockholders' equity decreased from $263.1 million at December 31, 2024, to $133.0 million at September 30, 2025.
• Net cash used in operating activities was $(19.5) million for the nine months ended September 30, 2025, a significant shift from $13.5 million provided in the prior year period.

Risks

• Significant operating losses since inception and no assurance of sustained profitability.
• Reliance on sales of insulin pump products, with any negative factors potentially adversely affecting business, financial condition, and operating results.
• Ability to maintain and grow revenue depends in part on retaining a high percentage of the customer base.
• Failure to secure or retain adequate coverage or reimbursement for current and future products by third-party payors could adversely affect business.
• Operating in a very competitive industry, with potential failure to compete successfully against existing or future competitors.
• Competing products, therapeutic techniques, or other technological developments for diabetes treatment may render products obsolete or less desirable.
• Unexpected challenges in marketing and selling products, and training new customers, could harm ability to achieve sales forecasts.
• Dependence on independent distributors in the United States who are free to market competing products.
• Dependence on clinical investigators and sites to enroll participants in trials; failure could prevent regulatory clearances or commercialization.
• Concerns regarding the safety or efficacy of products could limit sales and cause unforeseen negative effects.
• Dependence on a limited number of third-party suppliers for certain components and products; loss or inability to supply could harm business.
• Commercializing products outside of the United States may result in various risks associated with international operations.
• Significant amount of indebtedness, with agreements governing such indebtedness restricting financial flexibility.
• May need to raise additional funds in the future; inability to do so could prevent achievement of strategic objectives.
• Operating results may fluctuate significantly from quarter to quarter.
• Potential negative impact of changing the pricing model for pumps and supplies sold through the pharmacy channel.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business.
• Uncertainty in current global economic and political conditions could adversely affect ability to predict product demand.
• Sales and profits may fluctuate or decline in response to changes in foreign currency exchange rates or other international risks.
• The effects of inflation could adversely affect the business.
• Subject to stringent and evolving United States and foreign laws, regulations, and rules, contractual obligations, policies, and other obligations related to data privacy and security; failure to comply could lead to regulatory investigations, litigation, fines, and reputational harm.
• Information technology systems or those of third parties, data, or software being compromised could lead to adverse consequences.
• Ability to comprehensively protect intellectual property and proprietary technology is uncertain.
• Patent litigation in the medical device industry is common and could cause substantial costs and divert management attention.
• May be subject to damages from claims of wrongful use or disclosure of trade secrets.
• May incur product liability losses, and insurance coverage may be inadequate or unavailable.
• Adhering to regulations concerning public company corporate governance and reporting requirements may strain resources and distract management.
• Products and operations are subject to extensive governmental regulation; failure to comply could cause business to suffer.
• A recall or suspension of products, or the discovery of serious safety issues, could have a significant negative impact.
• Failure to comply with United States federal and state fraud and abuse laws, or comparable foreign legislation, could have a material adverse impact.
• Legislative or regulatory healthcare reforms may result in downward pressure on prices and decreased reimbursement for products.
• Governments outside the United States tend to impose strict price controls, reimbursement approval, and rebate policies.
• Advertising and promotion, especially comparative claims, could expose the company to heightened regulatory scrutiny and litigation.
• Direct-to-consumer marketing and social media initiatives may subject the company to increased regulatory scrutiny.
• Environmental, social, and governance (ESG) regulations, initiatives, and policies could expose the company to various risks.
• Climate change or other extreme weather conditions and related regulations may have a long-term impact on the business.
• The price of common stock may continue to fluctuate significantly.
• Dependence on the knowledge and skills of senior management and other key employees; inability to retain or recruit could harm business.
• Anti-takeover provisions in organizational documents and Delaware law may delay or prevent a change of control.
• Failure to successfully manage acquisitions or investments, or integrate them, could have a material adverse effect.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited.
• Uncertainties in the interpretation and application of existing, new, and proposed tax laws and regulations could materially affect tax obligations and effective tax rate.

Future Outlook

The company aims to redefine global leadership in insulin delivery by offering a flexible portfolio of intelligent insulin delivery systems, including enhancing the t:slim X2 and Tandem Mobi platforms. Future technology plans include a tubeless, extended-wear infusion site option for Tandem Mobi, a next-generation patch pump (marketed as next-gen Tandem Mobi using Sigi Patch Pump technology), extended-wear infusion set technology, dual glucose-ketone sensor integration, and algorithm advancement towards fully closed-loop technology. The company expects expenses to continue increasing due to these objectives and investments, and plans to rely primarily on product sales to fund its cash requirements. It anticipates continued significant resource dedication by competitors in the insulin-dependent diabetes market and expects to increasingly rely on third parties for clinical trials. A strategic shift to a pharmacy benefit model for pumps and supplies is being implemented, which may initially decrease sales and gross profit but is expected to be offset by increased supply sales over time. Direct sales activities in select European countries are planned to begin in the first quarter of 2026.

Management Comments

• Our goal is to address the individual needs of people with insulin-dependent diabetes and their care team, by offering flexibility and choice in intelligent insulin delivery systems, through an accessible portfolio of market-leading pumps, applications, and insights.
• Our goal is to redefine global leadership in insulin delivery with an accessible portfolio of transformational devices, applications and services that reduce the daily burden of living with diabetes.
• We believe that our cash and cash equivalents, short-term investments, and future cash flows from operations will be sufficient to fund our ongoing core business activities for at least the next 12 months.
• We expect to rely primarily on product sales to fund our material cash requirements in both the short and long term.

Industry Context

The company operates in the global insulin delivery and diabetes technology market, primarily addressing Type 1 diabetes and expanding into Type 2 diabetes requiring intensive insulin therapy in the U.S. The industry is intensely competitive, with major players like Beta Bionics, Insulet, Medtronic, Sequel, and Ypsomed. The market is subject to rapid change, new product introductions, and evolving treatment techniques. The adoption of GLP-1 class drugs since 2023 has likely negatively impacted the insulin therapy market. Insulin pumps generally follow a four-year reimbursement cycle. There's an increasing focus on cost containment by government and private insurers. Regulatory environments are evolving, with new EU Health Technology Assessment (HTA) regulations applicable since January 2025 and updated UK Medical Devices Regulations (UK MDR 2002) post-market surveillance requirements effective June 17, 2025, with further updates expected in 2026.

Comparison to Industry Standards

• The Tandem Mobi insulin pump is highlighted as the world's smallest durable automated insulin delivery (AID) system, positioning it competitively against other market offerings.
• The t:slim X2 was the first pump in the industry to offer remote software updates commercially in the United States, a feature now available worldwide, which the company believes is a competitive advantage.
• Multiple studies, including four publications in the New England Journal of Medicine (most recent in March 2025), demonstrate that Control-IQ+ technology and its predecessor, Control-IQ technology, are associated with improved clinical outcomes for people with type 1 or type 2 diabetes, suggesting strong clinical efficacy compared to general standards.
• The company's primary competitors are identified as major medical device companies: Beta Bionics, Insulet, Medtronic, Sequel, and Ypsomed, indicating a highly competitive landscape.
• Some competitors employ aggressive pricing strategies, including discounts, rebates, and low-cost product upgrades, which could adversely affect the company's sales and market share.

Legal Proceedings

• On May 21, 2025, the company entered into a Settlement, Mutual Release and Cross-License Agreement with various Roche entities, resolving all actual or potential patent disputes as of the agreement date, including actions pending before courts of the Unified Patent Court in France and Germany.
• The company is involved in various legal proceedings, regulatory matters, and other disputes or claims arising from or related to normal business activities, including intellectual property, data privacy, employment, regulatory, product liability, and contractual matters.
• As of September 30, 2025, the company believes it is not currently a party to any legal proceedings, regulatory matters, or other disputes or claims for which a material loss was considered probable or reasonably estimable.

Stakeholder Impact

• Shareholders face potential dilution from convertible notes and stock price volatility due to fluctuating operating results and significant one-time expenses.
• Customers benefit from new product offerings like Tandem Mobi and remote software updates for t:slim X2, but may be impacted by potential safety issues or changes in reimbursement models.
• Employees are affected by restructuring costs and the company's dependence on retaining key talent, with stock-based compensation being a significant component of their remuneration.
• Suppliers face risks due to the company's reliance on a limited number of third-party suppliers for critical components, which could lead to supply chain disruptions.
• Creditors are exposed to the company's significant indebtedness from convertible senior notes, requiring substantial cash flow for debt service payments.

Next Steps

• Pursue additional regulatory and pre-commercial activities, including securing in-country registrations and reimbursement, before launching Tandem Mobi outside the United States.
• Continue to scale Tandem Source into additional countries.
• Enhance features and capabilities of the t:slim X2 and Tandem Mobi insulin pump platforms.
• Add a tubeless, extended-wear infusion site option for Tandem Mobi users.
• Develop a next-generation patch pump incorporating Sigi Patch Pump technology, anticipated to be marketed as the next generation Tandem Mobi.
• Advance development efforts for extended-wear infusion set technology, dual glucose-ketone sensor integration, and algorithm advancement towards fully closed-loop technology.
• Initiate direct sales activities in select European countries, expected to begin in the first quarter of 2026.
• Evaluate ASU 2023-09, ASU 2024-03, and ASU 2025-06 to determine their impact on consolidated financial statements.

Key Dates

Recommendation

While Tandem Diabetes Care demonstrated revenue growth and improved gross margins for both the quarter and year-to-date, the significant increase in year-to-date net loss and operating loss, primarily due to substantial one-time charges for acquired IPR&D and litigation settlement, presents a mixed financial picture. The company's cash position improved, and strategic initiatives like the Tandem Mobi CE Mark and multi-channel reimbursement strategy are positive for future growth. However, the negative operating cash flow for the nine-month period and the reduction in stockholders' equity highlight ongoing financial pressures. Given the operational improvements alongside significant non-recurring expenses and a highly competitive, regulated industry, a 'hold' recommendation is appropriate. This acknowledges the company's potential for long-term growth through its product pipeline and market expansion, while recognizing the current financial challenges and inherent risks that warrant careful monitoring before a more definitive stance.

Keywords

Insulin Pump, Diabetes Technology, Automated Insulin Delivery, Tandem Mobi, t:slim X2, Control-IQ+, CGM Integration, Medical Device, SEC Filing, 10-Q, Financial Results, Healthcare, Biomedical, Regulatory Approval, Reimbursement, Convertible Notes, R&D, Corporate Governance, Risk Factors